The probability of a complete and disability-free recovery from an acute ischemic stroke is considerably increased by reperfusion, whether it be accomplished through intravenous thrombolytic drug therapy or, in some cases, endovascular mechanical thrombectomy. Intravenous thrombolysis is becoming less common due to the limited window of opportunity for therapy, and each patient must assess the possible advantages against the dangers of symptomatic cerebral haemorrhage. Pre-hospital and in-hospital paths should be optimized because shorter onset-to-reperfusion periods are more advantageous. While hemorrhage is more common in more severe strokes, a higher percentage of patients are disability free after therapy unless they suffer from a hemorrhagic consequence. There are a few rare side effects include swelling of the face, tongue and extra-cranial bleeding. Individuals who have substantial arterial blockage seen on imaging may occasionally benefit from endovascular mechanical thrombectomy. Effective treatment plans require well-coordinated services that can deliver care quickly in settings with the required resources (staff and equipment). It surges the incidence to return to independence greatly when a patient receives an intravenous recombinant tissue plasminogen activator (IV rtPA) within 4.5 hours of the spawn of symptoms. Shorter onset-to-treatment periods are associated with greater benefits; thus services should reduce treatment delay as much as possible. The most serious side effect of IV rtPA is symptomatic cerebral haemorrhage. The choice of treatment depends on weighing the likelihood of a positive clinical outcome against the danger of cerebral bleeding. A subgroup of large vessel occlusion patients benefits from endovascular mechanical thrombectomy in terms of their odds of a successful outcome. Endovascular operations can have vascular access, radiographic contrast media and vascular damage as side effects.